Six New Assays Added to Specialist Protein Analyzer
|
By LabMedica International staff writers Posted on 27 Feb 2012 |

Image: SPAplus protein analyzer with kit (Photo courtesy of Binding Site).
Six fully automated, easy-to-use assays were added to a specialist protein analyzer. They provide quantitative results to aid the assessment of a patient’s immune system.
The six assays include four cerebrospinal fluid (CSF) assays: immunoglobulin G (IgG), IgA, IgM, and albumin. Complement 1(C1) inactivator in plasma and serum, for the investigation of hereditary angioedema, and transferrin in serum, for estimation of iron deficiency anaemia, were also added to the analyzer menu.
These additions complement the panel of assays currently available on SPAplus including Hevylite immunoglobulin heavy chain/light chain assays, Freelite serum free light chain assays, and various complement assays.
Binding Site’s (Birmingham, United Kingdom) SPAplus specialist protein analyzer was designed to bring together instrument, reagents, and support as a package. A compact, turbidimetric platform, the fully automated SPAPLUS system enables laboratories to maintain the quality of results and high throughput required for specialized protein assays. It can be placed alongside the laboratory’s main-line analyzers or in other areas of the laboratory.
Preprogrammed protocols, developed and manufactured by Binding Site, provide sensitive and reproducible results that match or have greater sensitivity than nephelometry. The modular design with intuitive Windows based software makes the SPAplus very easy to use.
SPAplus has an expanding menu of diagnostic tests related to disease state management and clinical practice guidelines. More assays will be added during 2012.
Related Links:
Binding Site
The six assays include four cerebrospinal fluid (CSF) assays: immunoglobulin G (IgG), IgA, IgM, and albumin. Complement 1(C1) inactivator in plasma and serum, for the investigation of hereditary angioedema, and transferrin in serum, for estimation of iron deficiency anaemia, were also added to the analyzer menu.
These additions complement the panel of assays currently available on SPAplus including Hevylite immunoglobulin heavy chain/light chain assays, Freelite serum free light chain assays, and various complement assays.
Binding Site’s (Birmingham, United Kingdom) SPAplus specialist protein analyzer was designed to bring together instrument, reagents, and support as a package. A compact, turbidimetric platform, the fully automated SPAPLUS system enables laboratories to maintain the quality of results and high throughput required for specialized protein assays. It can be placed alongside the laboratory’s main-line analyzers or in other areas of the laboratory.
Preprogrammed protocols, developed and manufactured by Binding Site, provide sensitive and reproducible results that match or have greater sensitivity than nephelometry. The modular design with intuitive Windows based software makes the SPAplus very easy to use.
SPAplus has an expanding menu of diagnostic tests related to disease state management and clinical practice guidelines. More assays will be added during 2012.
Related Links:
Binding Site
Latest Technology News
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








